Zhenyuan Solid Drink Ameliorates Inflammation and Oxidative Stress in Isoproterenol-Induced Ischemic Myocardial Infarction via TLR4/NF-κB Pathway and PI3K/AKT1/NRF2 Pathway in Rats.

Huang Jiawen; Yu Tian; Li Guoyi; Nie Kechao; Liu Donghua; Meng Cong; Shen Xiaoling; Fu Linchun; Long Liang; Fu Zhuotao; Deng Zhitong; Hu Yingjie
Food science & nutrition 2026
Open on PubMed

Zhenyuan Solid Drink (ZYSD) is a formulation consisting of 6 medicinal herbs that can be used as both food and medicinal materials in China. This comprehensive analysis aims to illuminate the potential therapeutic effects and underlying mechanisms of ZYSD in the context of ischemic myocardial infarction. Marker components in ZYSD were identified by high performance liquid chromatography (HPLC) through comparison with reference compounds. Isoproterenol (ISO)-induced rats were employed as the in vivo model of ischemic myocardial infarction. Subsequently, a multi-tiered approach integrating cardiac color Doppler ultrasound, cardiac enzyme marker analysis, inflammatory factor detection, gut microbiota profiling, network pharmacology, molecular docking, molecular dynamics (MD) simulation, and western blot analysis was employed to elucidate the effects and underlying mechanisms of ZYSD, with intervention in alleviating metoprolol tartrate as positive control. Ten compounds, derived from 6 medicinal plants, in ZYSD were identified as marker components for the quality control via HPLC. Animal studies confirmed the preventive and therapeutic efficacy of ZYSD against ischemic myocardial infarction, as evidenced by the improvement of cardiac function and the attenuation of inflammation and oxidative stress. Using network pharmacology and molecular docking, the active constituents including marker compounds of ZYSD exhibited strong binding affinity to their key targets, including AKT1 and NRF2. MD simulation further indicated the binding interaction between ZYSD components and AKT1. Western blot analysis results further verified that ZYSD regulates the TLR4/NF-κB pathway and PI3K/AKT1/NRF2 pathway. Collectively, our findings demonstrate that ZYSD mitigates inflammation and oxidative stress, potentially through the TLR4/NF-κB and PI3K/AKT1/NRF2 pathways, thereby providing a novel strategy for the prevention and treatment of ischemic myocardial infarction.

10 Figures Extracted
FIGURE 1
FIGURE 1 PMC
Experimental procedure schematic diagram. (A) Schematic diagram of pre‐intervention experiment with isoproterenol‐induced ischemic myocardial infarcti...
FIGURE 2
FIGURE 2 PMC
HPLC chromatograms for the reference compounds (A) and ZYSD (B). Identified plant constituent: 1‐liquiritin, 2‐ginsenosides Rb3, 3‐epimedin A, 4‐epime...
FIGURE 3
FIGURE 3 PMC
ZYSD prevention improved cardiac function in isoproterenol‐induced rats with ischemic myocardial infarction. (A) Ejection fraction of the rat hearts i...
FIGURE 4
FIGURE 4 PMC
ZYSD prevention reduced inflammation and oxidative stress in isoproterenol‐induced rats with ischemic myocardial infarction. (A) Levels of TNF‐α, IL‐1...
FIGURE 5
FIGURE 5 PMC
ZYSD treatment improved cardiac function in isoproterenol‐induced rats with ischemic myocardial infarction. (A) Ejection fraction of the rat hearts in...
FIGURE 6
FIGURE 6 PMC
ZYSD treatment reduced inflammation and oxidative stress in isoproterenol‐induced rats with ischemic myocardial infarction. (A) Levels of TNF‐α, IL‐1β...
FIGURE 7
FIGURE 7 PMC
ZYSD treatment up‐regulated beneficial bacterial genera that contribute to the improvement of ischemic myocardial infarction. (A) Shannon index. (B) P...
FIGURE 8
FIGURE 8 PMC
Network pharmacology and molecular docking analysis. (A) ZYSD active ingredient‐target network. (B) Venn diagram of active ingredients and disease tar...
FIGURE 9
FIGURE 9 PMC
Molecular dynamic simulation analysis. (A) Molecular dynamics simulation analyses for AKT1 protein, AKT1‐Epimedin C, AKT1‐Icariin, AKT1‐Salvianolic ac...
FIGURE 10
FIGURE 10 PMC
ZYSD prevention and treatment regulated TLR4/NFκB and PI3K/AKT1/NRF2 signaling pathway. (A–F) Western blotting analysis of TLR4, NFκB, p‐NFκB, NRF2, A...